Home » Stocks » PDS Biotechnology

PDS Biotechnology Corporation (PDSB)

Stock Price: $2.34 USD 0.10 (4.46%)
Updated Sep 25, 2020 4:00 PM EDT - Market closed
After-hours: $2.40 +0.06 (2.56%) Sep 25, 6:32 PM

Stock Price Chart

Key Info

Market Cap 52.09M
Revenue (ttm) n/a
Net Income (ttm) -16.84M
Shares Out 22.26M
EPS (ttm) -1.87
PE Ratio n/a
Forward PE n/a
Dividend n/a
Dividend Yield n/a

Stock Quote

Trading Day Sep 25, 2020
Last Price $2.34
Previous Close $2.24
Change ($) 0.10
Change (%) 4.46%
Day's Open 2.23
Day's Range 2.23 - 2.54
Day's Volume 388,547
52-Week Range 0.62 - 5.11

More Stats

Market Cap 52.09M
Enterprise Value 35.82M
Earnings Date (est) Nov 5, 2020
Ex-Dividend Date n/a
Shares Outstanding 22.26M
Float 17.63M
EPS (basic) -2.52
EPS (diluted) -1.87
FCF / Share -1.10
Dividend n/a
Dividend Yield n/a
Earnings Yield n/a
FCF Yield n/a
Payout Ratio n/a
Shares Short 542,032
Short Ratio 0.52
Short % of Float 3.68%
Beta n/a
PE Ratio n/a
Forward PE n/a
P/FCF Ratio n/a
PS Ratio n/a
PB Ratio 3.34
Revenue n/a
Operating Income -18.80M
Net Income -16.84M
Free Cash Flow -16.84M
Net Cash 16.27M
Net Cash / Share 0.73
Gross Margin n/a
Operating Margin n/a
Profit Margin n/a
FCF Margin n/a
ROA -40.42%
ROE -89.55%
ROIC 2,144.40%
Stats based on trailing-twelve-month (ttm) numbers.

Analyst Summary

Analyst Ratings (2)

Buy 2
Overweight 0
Hold 0
Underweight 0
Sell 0

Analyst Consensus: Buy

Price Target

(252.56% upside)
Current: $2.34
Target: 8.25
*Average 12-month price target from 2 stock analysts.

Financial Performance

Financial numbers in millions USD.

Financial Overview

Operating Income-21.03-3.65-51.97-39.51-26.50-13.19-6.49
Net Income-7.00-3.84-50.86-38.82-28.08-12.20-6.88
Shares Outstanding4.873.341.521.440.400.080.08
Earnings Per Share-1.44-1.15-33.40-26.80-80.20-163.20-94.20
Operating Cash Flow-18.07-1.57-40.70-32.19-21.75-9.72-8.04
Capital Expenditures0.28--0.19-0.69-1.31-0.88-0.14
Free Cash Flow-17.80-1.57-40.89-32.88-23.06-10.60-8.18
Cash & Equivalents12.160.1088.0710613013.737.86
Total Debt-0.0320.4614.955.302.59-
Net Cash / Debt12.160.0767.6191.4512511.147.86
Book Value11.70-2.0762.3789.28122-27.83-15.35
Numbers in millions USD, except per-share numbers.

Company Profile

Company Details

Full Name PDS Biotechnology Corporation
Country United States
Employees 13
CEO Frank K. Bedu-Addo

Stock Information

Ticker Symbol PDSB
Stock Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Unique Identifier NASDAQ: PDSB


PDS Biotechnology Corporation, a clinical-stage biopharmaceutical company, focuses on developing multifunctional cancer immunotherapies. Its lead product candidate is PDS0101 (HPV16), which is in Phase II clinical trial, a first line treatment for the recurrent/metastatic head and neck cancer, human papillomavirus associated malignancies, and cervical cancer. The company is also developing various product candidates, which are in preclinical trials, including PDS0102 (TARP) for treating prostate and breast cancers; PDS0103 (MUC-1) for ovarian, colorectal, lung, and breast cancers; and PDS0104 (TRP2) for the treatment of melanoma. The company has a collaboration agreement with Merck & Co. to combine PDS0101 with Keytruda, a checkpoint inhibitor to treat human papillomavirus positive recurrent or metastatic head and neck cancer; and an agreement with Farmacore Biotechnology for the development of Versamune-based vaccine to prevent COVID-19 infection. The company is based in Princeton, New Jersey.